Article

Rare ocular surface tumors often prove deadly

Author(s):

Nathan Hall, BS, MS, presents research on how epidemiologic analysis of malignant ocular surface tumors found significant differences in geographic prevalence rates in the United States.

Investigators found that prevalence rates of ocular surface tumors differed across all geographic areas

Investigators found that prevalence rates of ocular surface tumors differed across all geographic areas. (Image courtesy of Nathan Hall, MS, BS)

Reviewed by Nathan Eli Hall, BS, MS

An epidemiologic analysis of malignant ocular surface tumors, which are rare but serious events, found significant differences in geographic prevalence rates in the US with more Caucasian men and smokers affected, according to Nathan Hall, MS, BS, from the Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston.

Nathan Hall

Nathan Hall, MS, BS

Considering the seriousness of these tumors of the conjunctiva and/or cornea, patient morbidity and mortality can be affected, Hall pointed out, noting the importance of identifying the associated risk factors, such as ultraviolet light exposure in various regions, gender, and older age that can play a role. 

Hall and his colleagues conducted the analysis, which used data from the American Academy of Ophthalmology’s IRIS Registry, and included more than 15,000 patients who had been diagnosed with a malignant ocular surface tumor of the conjunctiva/cornea between 2013 and 2019.

The investigators found that prevalence rates of ocular surface tumors differed across all geographic areas, with the highest prevalence in the North Central region (0.0032 cases/100,000) and lowest in the West (0.0014 cases/100,000), Hall reported.

White males and smokers were most highly affected and non-white females were the least affected (p < 0.0001 for all comparisons). Hall also noted that smoking seems to have an impact on the prevalence because the investigators found a significantly higher proportion of current smokers within those patients with an ocular surface tumor than in the general IRIS Registry patient pool.

Investigators also pointed out that exposure to ultraviolet light and latitude-related differences have been reported previously as risk factors for ocular surface tumors in other studies, and including similar types of data in the IRIS Registry should be another path of investigation.

“Our results suggested a significantly higher prevalence of ocular surface tumors in white males and smokers, and differences between geographic area of the US,” Hall concluded.

See more AAO meeting coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.